The estimated Net Worth of Jeffrey M Soinski is at least $1.31 Million dollars as of 18 September 2022. Mr. Soinski owns over 1,250 units of Avinger Inc stock worth over $8,201 and over the last 9 years he sold AVGR stock worth over $5,411. In addition, he makes $1,292,540 as President, Chief Executive Officer und Director at Avinger Inc.
Jeffrey has made over 9 trades of the Avinger Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 1,250 units of AVGR stock worth $1,450 on 18 September 2022.
The largest trade he's ever made was buying 57,100 units of Avinger Inc stock on 16 August 2016 worth over $199,850. On average, Jeffrey trades about 2,754 units every 35 days since 2015. As of 18 September 2022 he still owns at least 7,070 units of Avinger Inc stock.
You can see the complete history of Mr. Soinski stock trades at the bottom of the page.
Jeffrey M. Soinski serves as President, Chief Executive Officer, Director of the Company. He has served as our President, Chief Executive Officer and a member of our Board of Directors since December 2014. From its formation in September 2009 until the acquisition of its Unisyn business by GE Healthcare in May 2013, Mr. Soinski served as Chief Executive Officer of Medical Imaging Holdings and its primary operating company Unisyn Medical Technologies, a national provider of technology-enabled products and services to the medical imaging industry. Mr. Soinski was a Director of Medical Imaging Holdings and its remaining operating company Consensys Imaging Service from September 2009 until its sale in October 2017. Mr. Soinski served periodically as a Special Venture Partner from July 2008 to June 2013 and as a Special Investment Partner since October 2016 for Galen Partners, a leading healthcare-focused private equity firm, which included Medical Imaging Holdings as one of its portfolio companies. From 2001 until its acquisition by C.R. Bard in 2008, Mr. Soinski was President and CEO of Specialized Health Products International, a publicly-traded manufacturer and marketer of proprietary safety medical products. Mr. Soinski served as a consultant to BLOXR Corporation, a venture-backed medical device company, from October 2013 until September 2014. He served on the board of directors of Merriman Holdings, parent of Merriman Capital, a San Francisco-based investment banking and brokerage firm, from 2008 until March 2016. Mr. Soinski holds a B.A. degree from Dartmouth College.
As the President, Chief Executive Officer und Director of Avinger Inc, the total compensation of Jeffrey Soinski at Avinger Inc is $1,292,540. There are no executives at Avinger Inc getting paid more.
Jeffrey Soinski is 57, he's been the President, Chief Executive Officer und Director of Avinger Inc since 2014. There are 5 older and 4 younger executives at Avinger Inc. The oldest executive at Avinger Inc is James Cullen, 77, who is the Independent Chairman of the Board.
Jeffrey's mailing address filed with the SEC is 400, Chesapeake Drive, Redwood City, San Mateo County, California, 94063, United States.
Over the last 10 years, insiders at Avinger Inc have traded over $4,931,811 worth of Avinger Inc stock and bought 65,650 units worth $291,405 . The most active insiders traders include John B Ph D Md Simpson, James Cullen und Jeffrey M Soinski. On average, Avinger Inc executives and independent directors trade stock every 57 days with the average trade being worth of $43,246. The most recent stock trade was executed by Nabeel Paul Subainati on 22 March 2023, trading 417 units of AVGR stock currently worth $484.
avinger, inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (pad). pad is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. the company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. avinger’s current lumivascular products include the lightbox imaging console, the ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or ctos, and pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in pad patients.
Avinger Inc executives and other stock owners filed with the SEC include: